A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|20|S1|22-33

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.20, Iss.S1, 2018-02, pp. : 22-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GLP-1 receptor agonists and HBA1c target of <7%% in type 2 diabetes: meta-analysis of randomized controlled trials

By Esposito K.   Mosca C.   Brancario C.   Chiodini P.   Ceriello A.   Giugliano D.  

Current Medical Research and Opinion, Vol. 27, Iss. 8, 2011-08 ,pp. : 1519-1528

Informa Healthcare

Access to resources Recommend Favorite

GLP‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond

By  

OBESITY, Vol. 23, Iss. 6, 2015-06 ,pp. : 1119-1129

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1065-1074

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomised Controlled Trials: Part 1, Design

By Deane Katherine H O  

The British Journal of Occupational Therapy, Vol. 69, Iss. 5, 2006-05 ,pp. : 217-223

College of Occupational Therapists

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A.   Ballantine Jane  

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite